Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review

References

• DevauxSCastelaAArchierEAdherence to topical treatment in psoriasis: a systematic literature reviewJ Eur Acad Dermatol Venereol201226Suppl 3616722512682
   PubMed Web of Science ®Google Scholar
• FidderHHSingendonkMMvan der HaveMOldenburgBvan OijenMGLow rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic reviewWorld J Gastroenterol201319274344435023885145
   PubMed Web of Science ®Google Scholar
• HelliwellPCoatesLChandranVQualifying unmet needs and improving standards of care in psoriatic arthritisArthritis Care Res2014661217591766
   PubMed Web of Science ®Google Scholar
• RathbunAMReedGWHarroldLRThe temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic reviewRheumatology201352101785179423236191
   PubMed Web of Science ®Google Scholar
• HelmickCGFelsonDTLawrenceRCEstimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part IArthritis Rheum2008581152518163481
   PubMed Web of Science ®Google Scholar
• VandeverLRheumatoid arthritis by the numbers: facts, statistics, and you Available from: http://www.healthline.com/health/rheumatoid-arthritis/facts-statistics-infographicAccessed April 19, 2017
   Google Scholar
• Arthritis FoundationHow common is psoriatic arthritis in people with psoriasis? Available from: http://blog.arthritis.org/psoriatic-arthritis/psoriatic-arthritis-psoriasis/Accessed April 19, 2017
   Google Scholar
• RachakondaTDSchuppCWArmstrongAWPsoriasis prevalence among adults in the United StatesJ Am Acad Dermatol201470351251624388724
   PubMed Web of Science ®Google Scholar
• CramerJARoyABurrellAFairchildCJFuldeoreMJOllendorfDAWongPKMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
   PubMed Web of Science ®Google Scholar
• CramerJRosenheckRKirkGKrolWKrystalJVA Naltrexone Study Group 425Medication compliance feedback and monitoring in a clinical trial: predictors and outcomesValue Health20036556657314627063
   PubMed Web of Science ®Google Scholar
• HaynesRBMcdonaldHGargAXMontaguePInterventions for helping patients to follow prescriptions for medicationsCochrane Database Syst Rev20022279
   Google Scholar
• HaynesRBMcdonaldHPGargAXHelping patients follow prescribed treatment: clinical applicationsJAMA2002288222880288312472330
   PubMed Web of Science ®Google Scholar
• OsterbergLBlaschkeTAdherence to medicationN Engl J Med2005353548749716079372
   PubMed Web of Science ®Google Scholar
• IugaAOMcguireMJAdherence and health care costsRisk Manag Healthc Policy20147354424591853
   PubMedGoogle Scholar
• BlumMAKooDDoshiJAMeasurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic reviewClin Ther201133790191321715007
   PubMed Web of Science ®Google Scholar
• HarroldLRAndradeSEMedication adherence of patients with selected rheumatic conditions: a systematic review of the literatureSemin Arthritis Rheum200938539640218336875
   PubMed Web of Science ®Google Scholar
• PasmaAvan’t SpijkerAHazesJMBusschbachJJLuimeJJFactors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic reviewSemin Arthritis Rheum2013431182823352247
   PubMed Web of Science ®Google Scholar
• ThorneloeRJBundyCGriffithsCEAshcroftDMCordingleyLAdherence to medication in patients with psoriasis: a systematic literature reviewBr J Dermatol20131681203122963128
   PubMed Web of Science ®Google Scholar
• VangeliEBakhshiSBakerAA systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseasesAdv Ther20153211983102826547912
   PubMed Web of Science ®Google Scholar
• ViswanathanMBerkmanNDDrydenDMHartlingLAssessing Risk of Bias and Confounding in Observational Studies of Interventions or Exposures: Further Development of the RTI Item BankRockville, MDAgency for Healthcare Research and Quality2013
   Google Scholar
• ChuLHKawatkarAAGabrielSEMedication adherence and attrition to biologic treatment in rheumatoid arthritis patientsClin Ther201537366066625618317
   PubMed Web of Science ®Google Scholar
• ErhardtDSauerBTengCCClinical practice experience in rheumatoid arthritis patients treated with triple therapy and methotrexate-tumor necrosis factor inhibition differs from that of randomized controlled trialsArthritis Rheumatol201567Suppl 103197
   Google Scholar
• OladapoABarnerJCLawsonKANovakSRascatiKLRichardsKMHarrisonDJMedication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritisJ Manag Care Spec Pharm201420765766724967519
   PubMed Web of Science ®Google Scholar
• TkaczJEllisLBolgeSCMeyerRBradyBLRuetschCUtilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patientsClin Ther201436573774724661783
   PubMed Web of Science ®Google Scholar
• LiPBlumMAvon FeldtJHennessySDoshiJAAdherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritisValue Health201013680581221054657
   PubMed Web of Science ®Google Scholar
• BorahBJHuangXZarotskyVGlobeDTrends in RA patients’ adherence to subcutaneous anti-TNF therapies and costsCurr Med Res Opin20092561365137719425902
   PubMed Web of Science ®Google Scholar
• GrijalvaCGKaltenbachLArbogastPGMitchelEFGriffinMRAdherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admissionArthritis Care Res2010625730734
   Web of Science ®Google Scholar
• HarleyCRFrytakJRTandonNTreatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexateAm J Manag Care200396 SupplS136S14314577718
   PubMed Web of Science ®Google Scholar
• CurkendallSPatelVGleesonMCampbellRSZagariMDuboisRCompliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?Arthritis Rheum200859101519152618821651
   PubMed Web of Science ®Google Scholar
• GrijalvaCGChungCPArbogastPGSteinCMMitchelEFGriffinMRAssessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritisMed Care20074510 Suppl 2S66S7617909386
   PubMed Web of Science ®Google Scholar
• BarlowJFFarisRJWangWVerbruggeRRGaravagliaSBAubertREImpact of specialty pharmacy on treatment costs for rheumatoid arthritisAm J Pharm Benefits201246SP49SP56
   Google Scholar
• EllisLBolgeSRicePGolimumab utilization patterns and refill adherence in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitisValue Health2014173A49A50
   Web of Science ®Google Scholar
• StocklKMShinJSLewHCZakharyanAHaradaASSolowBKCurtisBSOutcomes of a rheumatoid arthritis disease therapy management program focusing on medication adherenceJ Manag Care Pharm201016859360420866164
   PubMed Web of Science ®Google Scholar
• BonafedeMJohnsonBHTangDHShahNHarrisonDJCollierDHEtanercept-methotrexate combination therapy initiators have greater adherence and persistence than triple therapy initiators with rheumatoid arthritisArthritis Care Res2015671216561663
   Web of Science ®Google Scholar
• SandovalLFHuangKEFeldmanSRAdherence to ustekinumab in psoriasis patientsJ Drugs Dermatol201312101090109224085042
   PubMed Web of Science ®Google Scholar
• DoshiJATakeshitaJPintoLBiologic adherence among psoriasis patients in the US Medicare populationValue Health2015183A186
   Web of Science ®Google Scholar
• BhosleMJFeldmanSRCamachoFTTimothy WhitmireJNahataMCBalkrishnanRMedication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasisJ Dermatolog Treat200617529430117092860
   PubMed Web of Science ®Google Scholar
• LiYZhouHCaiBKahlerKHTianHGabrielSArconaSGroup-based trajectory modeling to assess adherence to biologics among patients with psoriasisClinicoecon Outcomes Res2014619720824748809
   PubMedGoogle Scholar
• GorenACarterCLeeSPatient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasisJ Dermatolog Treat2016271435026088404
   PubMed Web of Science ®Google Scholar
• KamangarFIsipLBhutaniTHow psoriasis patients perceive, obtain, and use biologic agents: survey from an academic medical centerJ Dermatolog Treat2013241132422007699
   PubMed Web of Science ®Google Scholar
• ShimAPhamHFairmanKAssociation of medication persistency with route of administration and patient cost-sharing: analysis of commonly used biologicsValue Health2015187A650
   Web of Science ®Google Scholar
• SauerBCTengCCHeTTreatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasisJ Med Econ2016191344326337538
   PubMed Web of Science ®Google Scholar
• GuTShahNDeshpandeGTangDHEisenbergDHarrisonDJPersistence with first-line biologics used in rheumatoid arthritis in a US managed care populationValue Health2015183A168
   Web of Science ®Google Scholar
• HoweAEyckLTDufourRShahNHarrisonDJTreatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial databaseJ Manag Care Spec Pharm201420121236124425443517
   PubMed Web of Science ®Google Scholar
• FisherMDWatsonCFoxKMChenYWGandraSRDosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care populationCurr Med Res Opin201329556156823489410
   PubMed Web of Science ®Google Scholar
• GreenbergJDReedGDecktorDA comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registryAnn Rheum Dis20127171134114222294625
   PubMed Web of Science ®Google Scholar
• TangBRahmanMWatersHCCallegariPTreatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritisClin Ther20083071375138418691998
   PubMed Web of Science ®Google Scholar
• YaziciYKrasnokutskySBarnesJPHinesPLWangJRosenblattLChanging patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritisJ Rheumatol200936590791319332636
   PubMed Web of Science ®Google Scholar
• CannonGWDuvallSLHaroldsenCLPersistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritisJ Rheumatol201441101935194325128516
   PubMed Web of Science ®Google Scholar
• MarkensonJAGibofskyAPalmerWRKeystoneECSchiffMHFengJBaumgartnerSWPersistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registryJ Rheumatol20113871273128121572150
   PubMed Web of Science ®Google Scholar
• AgarwalSKGlassRJShadickNAPredictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritisJ Rheumatol20083591737174418634159
   PubMed Web of Science ®Google Scholar
• AgarwalSKMaierALChibnikLBPattern of infliximab utili-zation in rheumatoid arthritis patients at an academic medical centerArthritis Rheum200553687287816342095
   PubMed Web of Science ®Google Scholar
• BolgeSCGorenATandonNReasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspectivePatient Prefer Adherence2015912113125653505
   PubMed Web of Science ®Google Scholar
• BonafedeMJohnsonBHFoxKMWatsonCGandraSRTreatment patterns with etanercept and adalimumab for psoriatic diseases in a real-world settingJ Dermatolog Treat201324536937323441722
   PubMed Web of Science ®Google Scholar
• ChastekBFoxKMWatsonCKricorianGGandraSRPsoriasis treatment patterns with etanercept and adalimumab in a United States health plan populationJ Dermatolog Treat2013241253322668321
   PubMed Web of Science ®Google Scholar
• FeldmanSRZhaoYNavaratnamPFriedmanHSLuJTranMHPatterns of medication utilization and costs associated with the use of etanercept, adalimumab, and ustekinumab in the management of moderate-to-severe psoriasisJ Manag Care Spec Pharm201521320120925726029
   PubMed Web of Science ®Google Scholar
• CaoZCarterCWilsonKLSchenkelBDosingUUstekinumab dosing, persistence, and discontinuation patterns in patients with moderate-to-severe psoriasisJ Dermatolog Treat201526211312024552612
   PubMed Web of Science ®Google Scholar
• MeasePJCollierDHSaundersKCLiGKremerJMGreenbergJDComparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registryRMD Open201511e00018126819748
   PubMedGoogle Scholar
• ChastekBFoxKMWatsonCGandraSREtanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health planAdv Ther201229869169722903239
   PubMed Web of Science ®Google Scholar
• KwiatkowskiAGrisantiLGrisantiJHatemJPatient preferences regarding route of biologic administration in an inflammatory arthritis cohortArthritis Rheumatol201567Suppl 102326
   Google Scholar
• ZhangJXieFDelzellESPersistence on biologics is associated with concomitant methotrexate use among rheumatoid arthritis patientArthritis Rheum201365S990S991
   Google Scholar
• MenterAPappKKruegerGGPersistence of biologic therapy in psoriatic disease: results from the psoriasis longitudinal assessment and registryArthritis Rheum201466S693
   Web of Science ®Google Scholar
• ZhangJXieFDelzellEImpact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patientsArthritis Care Res2015675624632
   Web of Science ®Google Scholar